Medtronic

Medtronic is offering its shareholders the option to exchange common shares at a 7% discount for up to 225.4 million MiniMed shares. The exchange ratio is capped at 4.5939 MiniMed shares per Medtronic common share; participating shareholders would receive MiniMed shares worth about $107.53 for every $100 of Medtronic shares, unless the cap applies. The aim is to spin off at least 80.1% of MiniMed; if oversubscribed, an additional 27.45 million shares may be exchanged, otherwise spin-off, split-off or debt-for-equity options are planned. Pricing will be based on the volume-weighted average price over three trading days ending Oct. 5–7; Medtronic shares rose 2.8% on the news. » Więcej na de.investing.com

Medtronic reported fiscal Q1 revenue of about $9.8 billion, up 13.7% organically, and non-GAAP EPS of $1.45, driving an increase in full-year organic revenue and EPS guidance. Cardiovascular revenue rose 18.9% with Cardiac Ablation Solutions up 88%, while Neuroscience and Medical Surgical also posted solid gains. The quarter benefited from an extra fiscal week (~$570 million) and showed only a 10 basis-point expansion in non-GAAP operating margin to 23.7%. Management is progressing with the planned MiniMed/diabetes separation and is investing in surgical robotics and Pi-Cardia, but faces competitive and margin risks going forward. » Więcej na finance.yahoo.com

Medtronic has refocused its business by exiting noncore units, spinning off its diabetes division and investing in new technology such as the Hugo surgical robot. The company reported its highest annual revenue growth in a decade in fiscal 2026 and Q1 fiscal 2027 revenues rose 13.7% with earnings above guidance, prompting an increased full-year outlook. Management says the business has passed an inflection point while the stock has gained about 15% over three months but remains roughly 30% below its 2021 high. Medtronic also retains a well-above-market dividend yield and a 48-year streak of annual dividend increases. » Więcej na finance.yahoo.com

Medtronic Diabetes sees accelerated US growth and is preparing multiple product launches, including MiniMed Fit (FDA submission, market launch summer 2027) and Vivera (2H 2027). The company confirms its FY27 guidance for adjusted organic growth of 9–9.5% and an adjusted EBITDA margin of 16%. Management cites production ramp-up, customer buying hesitation and the trade-off between growth and margins as main risks, but highlights positive manufacturing metrics at Simplera and channel expansion, particularly via pharmacies and Type‑2 patients. » Więcej na de.investing.com

Medtronic reported fiscal Q1 revenue of $9.8 billion, up 13.7% organic, and adjusted EPS of $1.45, topping expectations. The company raised its full-year guidance to 7.25%–7.75% organic revenue growth and adjusted EPS of $5.94–$6.00. Cardiovascular led performance, with Cardiac Ablation Solutions up 88% worldwide (139% in the U.S.) driven by Sphere‑9 and Affera, while CRM grew 15% and gained share. Management reiterated plans to separate the MiniMed diabetes business before year‑end and continues investments in Hugo surgical robotics and a $700 million Cornerstone Robotics agreement. » Więcej na finance.yahoo.com